Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Gastrointestinal tumours, non-colorectal

1422MO - Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study

Date

18 Sep 2020

Session

Mini Oral - Gastrointestinal tumours, non-colorectal

Presenters

Kensei Yamaguchi

Citation

Annals of Oncology (2020) 31 (suppl_4): S841-S873. 10.1016/annonc/annonc284

Authors

K. Yamaguchi1, Y. Bang2, S. Iwasa3, N. Sugimoto4, M. Ryu5, D. Sakai6, H.C. Chung7, H. Kawakami8, H. Yabusaki9, J. Lee10, K. Saito11, Y. Kawaguchi11, T. Kamio12, A. Kojima13, M. Sugihara14, K. Shitara15

Author affiliations

  • 1 Gastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 2 Internal Medicine (medical Oncology), Seoul National University Hospital, 110-744 - Seoul/KR
  • 3 Department Of Experimental Therapeutics And Department Of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo/JP
  • 4 Medical Oncology, Osaka International Cancer Institute, 537-8511 - Osaka/JP
  • 5 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 6 Department Of Frontier Science For Cancer And Chemotherapy, Osaka University Hospital, 565-0871 - Osaka/JP
  • 7 Department Of Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 03722 - Seoul/KR
  • 8 Medical Oncology, Kindai University Hospital, 589-8511 - Osaka/JP
  • 9 Medical Oncology, Niigata Cancer Center Hospital, 951-8566 - Niigata/JP
  • 10 Division Of Hematology-oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 06351 - Seoul/KR
  • 11 Clinical Development, Daiichi Sankyo, Inc, Basking Ridge/US
  • 12 Pharmacovigilance Department, Daiichi Sankyo Co, Ltd, Tokyo/JP
  • 13 Oncology Clinical Development, Daiichi Sankyo Co, Ltd, Tokyo/JP
  • 14 Clinical Development, Daiichi Sankyo Co, Ltd, Tokyo/JP
  • 15 Department Of Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Chiba/JP
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1422MO

Background

T-DXd is an antibody-drug conjugate consisting of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a membrane-permeable topoisomerase I inhibitor payload. T-DXd is approved for the treatment of HER2-positive metastatic breast cancer in the US and Japan. T-DXd increased confirmed ORR (42.9% vs 12.5%) and OS (median, 12.5 vs 8.4 mo; HR, 0.59; P = .0097) vs chemotherapy in patients (pts) with HER2+ (IHC 3+; IHC 2+/ISH +) metastatic gastric or GEJ cancer in the primary cohort in the DESTINY-Gastric01 open-label, multicenter, phase II trial (NCT03329690). We present results from the HER2-low exploratory cohorts.

Methods

Pts with centrally confirmed HER2-low (IHC 2+/ISH− [cohort 1] or IHC 1+ [cohort 2] on archival tissue) that progressed on ≥ 2 prior lines of therapy were enrolled in Japan and Korea. Pts were excluded if they had prior HER2 therapy. The primary endpoint was ORR by independent central review.

Results

20 (cohort 1) and 24 (cohort 2) pts were treated with T-DXd 6.4 mg/kg q3w. Most were from Japan (cohort 1, 80.0%; cohort 2, 79.2%) and had received a median of 2 prior lines of therapy. At data cutoff (8 Nov 2019), no pts in cohort 1 and 2 in cohort 2 (8.3%) remained on treatment (median duration, 4.2 and 2.8 mo). In cohort 1, confirmed ORR was 26.3% (5/19, all PR); 12 pts had stable disease (DCR, 89.5%). Median PFS was 4.4 mo (95% CI, 2.7-7.1 mo); median OS was 7.8 mo (95% CI, 4.7 mo-NE), with a 12-mo OS rate of 40.0%. Confirmed ORR in cohort 2 was 9.5% (2/21, all PR); confirmed DCR was 71.4%. Median PFS and OS were 2.8 mo (95% CI, 1.5-4.3 mo) and 8.5 mo (95% CI, 4.3-10.9 mo), with a 12-mo OS rate of 25.7%. Grade ≥ 3 adverse events occurred in 70.0% and 79.2% of pts in cohorts 1 and 2. Decreased appetite (65.0%; 75.0%), nausea (55.0%; 79.2%), and neutrophil count decreased (45.0%; 50.0%) were most common. One pt in each cohort (grade 1 = 1; grade 2 = 1) had T-DXd–related interstitial lung disease.

Conclusions

T-DXd showed preliminary evidence of clinical activity in pts with previously treated, HER2-low gastric or GEJ cancer. The safety profile was similar to that in the HER2+ primary cohort.

Clinical trial identification

NCT03329690.

Editorial acknowledgement

Medical editorial assistance provided by John Togneri, PhD (Articulate Science LLC).

Legal entity responsible for the study

Daiichi Sankyo Co., Ltd.

Funding

Daiichi Sankyo Co., Ltd.

Disclosure

K. Yamaguchi: Speaker Bureau/Expert testimony, Research grant/Funding (institution): Cancer Institute Hospital of Japanese Foundation for Cancer Research; Honoraria (institution), Speaker Bureau/Expert testimony: Daiichi Sankyo ; Honoraria (institution), Speaker Bureau/Expert testimony: Taiho Pharmaceutical; Honoraria (institution), Speaker Bureau/Expert testimony: Chugai Pharm; Speaker Bureau/Expert testimony: Bristol-Myers Squibb Japan; Honoraria (institution), Speaker Bureau/Expert testimony: Ono Pharmaceutical; Speaker Bureau/Expert testimony: Takeda; Honoraria (institution), Speaker Bureau/Expert testimony: Lilly; Honoraria (institution), Speaker Bureau/Expert testimony: Sanofi; Honoraria (institution): MSD oncology; Honoraria (institution): Dainippon Sumitomo Pharma; Honoraria (institution): Gilead Sciences; Honoraria (institution): Boehringer Ingelheim; Honoraria (institution): Eisai; Honoraria (institution): Yakult Honsha. Y-J. Bang: Advisory/Consultancy: Samyung; Advisory/Consultancy, Research grant/Funding (institution): BeiGene; Advisory/Consultancy, Research grant/Funding (institution): Green Cross; Advisory/Consultancy, Research grant/Funding (institution): Taiho Pharmaceutical; Advisory/Consultancy, Research grant/Funding (institution): Merck Serono; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca/MedImmune; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): MSD Oncology; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy: Hanmi; Advisory/Consultancy, Research grant/Funding (institution): Genentech/Roche; Advisory/Consultancy, Research grant/Funding (institution): Lilly; Advisory/Consultancy, Research grant/Funding (institution): Daiichi Sankyo; Advisory/Consultancy, Research grant/Funding (institution): Astellas Pharma; Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy, Research grant/Funding (institution): Genexine; Advisory/Consultancy, Research grant/Funding (institution): GlaxoSmithKline; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Boehringer Ingelheim; Research grant/Funding (institution): Macrogenics; Research grant/Funding (institution): Boston Biomedical; Research grant/Funding (institution): Five Prime Therapeutics; Research grant/Funding (institution): Chong Kun Dang Pharmaceutical; Research grant/Funding (institution): Ono Pharmaceutical; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Curis. S. Iwasa: Research grant/Funding (institution): Daiichi Sankyo . N. Sugimoto: Research grant/Funding (institution): Daiichi Sankyo ; Research grant/Funding (institution): MSD; Research grant/Funding (institution): Astellas; Research grant/Funding (institution): Solasia; Research grant/Funding (institution): ONO; Research grant/Funding (self): Lilly; Research grant/Funding (self): Taiho. M-H. Ryu: Honoraria (self), Advisory/Consultancy: ONO; Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Lilly ; Honoraria (self), Advisory/Consultancy: Taiho; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Daehwa Pharmaceutical . D. Sakai: Speaker Bureau/Expert testimony, Research grant/Funding (institution): Chugai Pharma; Research grant/Funding (institution): Yakult Honsha; Research grant/Funding (institution): Ono Pharmaceutical; Research grant/Funding (self): Daiichi Sankyo; Research grant/Funding (self): Lilly Japan. H.C. Chung: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck-Serono; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Lilly; Advisory/Consultancy, Research grant/Funding (institution): Taiho; Advisory/Consultancy: Celltrion; Advisory/Consultancy, Research grant/Funding (institution): MSD; Advisory/Consultancy: Quintiles; Advisory/Consultancy, Research grant/Funding (institution): BMS/Ono; Advisory/Consultancy, Research grant/Funding (institution): Beigene; Advisory/Consultancy: Gloria; Advisory/Consultancy: AMGEN; Research grant/Funding (institution): GSK. H. Kawakami: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Daiichi Sankyo; Honoraria (self), Advisory/Consultancy: Bristol and Myers Squibb; Honoraria (self), Advisory/Consultancy: Ono pharmaceutical ; Honoraria (self), Advisory/Consultancy: Eli Lilly Japan; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Taiho; Honoraria (self), Research grant/Funding (institution): Chugai; Honoraria (self): Takeda; Research grant/Funding (institution): Eisai; Honoraria (self), Advisory/Consultancy: MSD KK. J. Lee: Advisory/Consultancy: Oncologie; Advisory/Consultancy: Seattle Genetics; Research grant/Funding (self): Astra Zeneca; Research grant/Funding (self): Merck Sharp and Dohme; Research grant/Funding (self): Eli Lilly and Company. K. Saito, T. Kamio, M. Sugihara: Full/Part-time employment: Daiichi Sankyo. Y. Kawaguchi: Shareholder/Stockholder/Stock options, Full/Part-time employment: Daiichi Sankyo . A. Kojima: Shareholder/Stockholder/Stock options, Full/Part-time employment: Daiichi Sankyo . K. Shitara: Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Abbvie; Honoraria (self): Yakult; Advisory/Consultancy, Research grant/Funding (institution): Astellas Pharma; Advisory/Consultancy, Research grant/Funding (institution): Lilly; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: Takeda; Advisory/Consultancy: Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Ono Pharmaceutical; Advisory/Consultancy, Research grant/Funding (institution): Taiho Pharmaceutica; Advisory/Consultancy, Research grant/Funding (institution): MSD; Advisory/Consultancy, Research grant/Funding (institution): GlaxoSmithKline; Advisory/Consultancy, Research grant/Funding (institution): Chugai Pharm; Research grant/Funding (institution): Medi Science; Research grant/Funding (institution): Daiichi Sankyo; Research grant/Funding (institution): Dainippon Sumitomo Pharma. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings